Clinical trials for severe sepsis - Past failures, and future hopes

被引：87

作者：

Opal, SM

Cross, AS

机构：

[1] Mem Hosp Rhode Isl, Div Infect Dis, Pawtucket, RI 02860 USA

[2] Brown Univ, Sch Med, Providence, RI 02912 USA

[3] Univ Maryland, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA

[4] UMD Sch Med, Greenebaum Canc Ctr, Program Infect Dis, Baltimore, MD USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 1999年 / 13卷 / 02期

关键词：

D O I：

10.1016/S0891-5520(05)70075-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recent clinical trials with experimental immunotherapeutic agents for severe sepsis and septic shock have been largely unsuccessful despite seemingly convincing preclinical evidence of significant benefit of these antisepsis therapies. This article reviews basic therapeutic rationale, preclinical evaluation, and clinical trial design of past clinical trials of innovative sepsis treatments. Lessons learned from past failures should provide insights into the design and implementation of successful clinical trials for new anti-sepsis agents in the future.

引用

页码：285 / +

页数：14

共 58 条

[41] LESSONS LEARNED FROM CLINICAL-TRIALS OF SEPSIS [J].